IONS vs DBVT vs REGN vs AZN vs BIIB

For growth investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger pick with 33. 9% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Ionis Pharmaceuticals, Inc. (IONS) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus AstraZeneca PLC at 27. 9x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AstraZeneca PLC wins at 0. 81x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Ionis Pharmaceuticals, Inc.

(IONS) delivered a total return of +108. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: AZN returned +268. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ionis Pharmaceuticals, Inc.

(IONS) is the lower-risk stock at 0. 55β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 131% more volatile than IONS relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ionis Pharmaceuticals, Inc.

(IONS) is pulling ahead at 33. 9% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, IONS leads at 17. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AstraZeneca PLC (AZN) is the more undervalued stock at a PEG of 0. 81x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 0x forward P/E versus 17. 7x for AstraZeneca PLC — 4. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, AZN (1.

8% yield), REGN (0. 5% yield) pay a dividend. IONS, DBVT, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +268. 6% 10Y return). Both have compounded well over 10 years (AZN: +268. 6%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IONS is a mid-cap high-growth stock; DBVT is a mega-cap quality compounder stock; REGN is a mid-cap deep-value stock; AZN is a large-cap quality compounder stock; BIIB is a mid-cap quality compounder stock. AZN pays a dividend while IONS, DBVT, REGN, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.